TY - JOUR
T1 - Down-regulation of Hepatic HNF4α Gene Expression during Hyperinsulinemia via SREBPs
AU - Xie, Xuefen
AU - Liao, Hailing
AU - Dang, Huaixin
AU - Pang, Wei
AU - Guan, Youfei
AU - Wang, Xian
AU - Shyy, John Y.J.
AU - Zhu, Yi
AU - Sladek, Frances M.
PY - 2009/4
Y1 - 2009/4
N2 - Mutations in the coding region of hepatocyte nuclear factor 4α (HNF4α), and its upstream promoter (P2) that drives expression in the pancreas, are known to lead to maturity-onset diabetes of the young 1 (MODY1). HNF4α also controls gluconeogenesis and lipid metabolism in the liver, where the proximal promoter (P1) predominates. However, very little is known about the role of hepatic HNF4α in diabetes. Here, we examine the expression of hepatic HNF4α in two diabetic mouse models, db/db mice (type 2, insulin resistant) and streptozotocin-treated mice (type 1, insulin deficient). We found that the level of HNF4α protein and mRNAwas decreased in the liver of db/db mice but increased in streptozotocin-treated mice. Because insulin increases the activity of sterol regulatory element-binding proteins (SREBP)-1c and -2, we also examined the effect of SREBPs on hepatic HNF4α gene expression and found that, like insulin, ectopic expression of SREBPs decreases the level of hepatic HNF4α protein and mRNA both in vitro in primary hepatocytes and in vivo in the liver of C57BL/6 mice. Finally, we use gel shift, chromatin immunoprecipitation, small interfering RNA, and reporter gene analysis to show that SREBP2 binds the human HNF4α P1 promoter and negatively regulates its expression. These data indicate that hyperinsulinemia down-regulates HNF4α in the liver through the up-regulation of SREBPs, thereby establishing a link between these two critical transcription factor pathways that regulate lipid and glucose metabolism in the liver. These findings also provide new insights into diabetes-associated complications such as fatty liver disease. (Molecular Endocrinology 23: 434-443, 2009)
AB - Mutations in the coding region of hepatocyte nuclear factor 4α (HNF4α), and its upstream promoter (P2) that drives expression in the pancreas, are known to lead to maturity-onset diabetes of the young 1 (MODY1). HNF4α also controls gluconeogenesis and lipid metabolism in the liver, where the proximal promoter (P1) predominates. However, very little is known about the role of hepatic HNF4α in diabetes. Here, we examine the expression of hepatic HNF4α in two diabetic mouse models, db/db mice (type 2, insulin resistant) and streptozotocin-treated mice (type 1, insulin deficient). We found that the level of HNF4α protein and mRNAwas decreased in the liver of db/db mice but increased in streptozotocin-treated mice. Because insulin increases the activity of sterol regulatory element-binding proteins (SREBP)-1c and -2, we also examined the effect of SREBPs on hepatic HNF4α gene expression and found that, like insulin, ectopic expression of SREBPs decreases the level of hepatic HNF4α protein and mRNA both in vitro in primary hepatocytes and in vivo in the liver of C57BL/6 mice. Finally, we use gel shift, chromatin immunoprecipitation, small interfering RNA, and reporter gene analysis to show that SREBP2 binds the human HNF4α P1 promoter and negatively regulates its expression. These data indicate that hyperinsulinemia down-regulates HNF4α in the liver through the up-regulation of SREBPs, thereby establishing a link between these two critical transcription factor pathways that regulate lipid and glucose metabolism in the liver. These findings also provide new insights into diabetes-associated complications such as fatty liver disease. (Molecular Endocrinology 23: 434-443, 2009)
UR - https://www.scopus.com/pages/publications/64749097992
U2 - 10.1210/me.2007-0531
DO - 10.1210/me.2007-0531
M3 - 文章
C2 - 19179483
AN - SCOPUS:64749097992
SN - 0888-8809
VL - 23
SP - 434
EP - 443
JO - Molecular Endocrinology
JF - Molecular Endocrinology
IS - 4
ER -